{"product_id":"supernus-bcg-matrix","title":"Supernus Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals is at an inflection point — this preview maps which products are pulling weight and which are draining cash, but the full BCG Matrix gives you quadrant-by-quadrant clarity and actionable strategy. Get the complete report to see exact placements, data-driven recommendations, and where to shift investment next. Purchase now for a ready-to-use Word report plus an Excel summary you can plug into your board materials. Skip the guesswork—get the full picture and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree (ADHD non‑stimulant)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQelbree has seen fast uptake in the expanding ADHD market (US ADHD prescription market \u0026gt;$12B in 2024), gaining share as a differentiated non‑stimulant with broad‑age labeling and a strong safety\/low abuse profile; high promotion intensity (field + DTC) has driven double‑digit share gains year‑over‑year, so continued investment in field and consumer marketing is warranted to cement leadership as the class grows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParkinson’s portfolio leaders (e.g., amantadine ER, apomorphine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eParkinson’s portfolio leaders like amantadine ER and apomorphine have strong brand recognition in movement‑disorder clinics and show real clinical differentiation in reducing dyskinesia and OFF time. Parkinsons affects ~10 million people worldwide and ~1 million in the US, projected to reach ~1.2 million by 2030, supporting category expansion. Capturing demand requires heavy patient‑support programs and specialty distribution; sustaining access and adding clinical\/outcomes data will compound revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology KOL footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeep KOL relationships with epilepsy specialists (epilepsy affects ~50 million people globally, WHO) and movement‑disorder experts (Parkinsons ~10 million, WHO) accelerate adoption across Supernus brands. Expanding a call universe of ~16,000 US neurologists (AAN) increases pull‑through and Rx volume. Sustained medical education and evidence generation are required to defend share, which then converts into a growth flywheel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel\/indication expansion engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLabel and indication expansions (line extensions) increase volume while preserving Supernus core CNS science; each approval or supplemental NDA in 2024 lifted product-level share during a neurology market growing roughly 5% YoY, making incremental ROI attractive despite upfront cash and multi-year trials.\u003c\/p\u003e\n\u003cp\u003eMaintain a warm pipeline of supplemental filings and Phase II\/III studies to sustain share gains; typical play requires high near-term spend but delivers above-cost-of-capital returns when category growth persists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eline-extensions\u003c\/li\u003e\n\u003cli\u003enew-indications\u003c\/li\u003e\n\u003cli\u003epipeline-warmth\u003c\/li\u003e\n\u003cli\u003e5%-market-growth-2024\u003c\/li\u003e\n\u003cli\u003eattractive-ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient services that remove friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient services that remove friction—access, affordability, adherence—drive persistency in Supernus growth categories and position these products as Stars in the BCG matrix. IQVIA 2024 found adherence programs raise medication persistency by ~20%, translating to higher effective share and revenue capture. These white‑glove programs cost (industry benchmark 5–8% of product revenue) but unlock sustained demand; maintain premium support to stay ahead.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess: streamline prior auth and distribution\u003c\/li\u003e\n\u003cli\u003eAffordability: co‑pay assistance reduces abandonment\u003c\/li\u003e\n\u003cli\u003eAdherence: ~20% persistency uplift (IQVIA 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑stimulant gains rapid share in \u0026gt;$12B US ADHD market; patient services lift persistence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQelbree drives rapid share in the \u0026gt;$12B US ADHD market (2024) as a differentiated non‑stimulant; continued field+DTC spend supports double‑digit YoY growth. Parkinsons portfolio (US ~1M patients, 2024) and epilepsy (global ~50M) show durable clinic pull‑through with specialty access needs. Patient services lift persistency ~20% (IQVIA 2024) at 5–8% revenue cost, justifying investment to keep these assets as Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS ADHD market\u003c\/td\u003e\n\u003ctd\u003e$12B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Parkinsons prevalence\u003c\/td\u003e\n\u003ctd\u003e~1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal epilepsy\u003c\/td\u003e\n\u003ctd\u003e~50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~20% (IQVIA 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport cost\u003c\/td\u003e\n\u003ctd\u003e5–8% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Supernus Pharmaceuticals: identifies Stars, Cash Cows, Question Marks, Dogs with strategic investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for Supernus Pharmaceuticals, pinpointing pain points and prioritizing units for faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpilepsy XR franchise (mature, high share)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpilepsy XR franchise (mature, high share) sustained \u0026gt;1.0 million prescriptions in 2024 with high patient retention and predictable refill cadence, supporting stable cash flow. Category growth was modest at ~3% in 2024 while gross margins remained healthy near 40%, keeping contribution margins strong. Lower promotional needs keep opex light; prioritize optimizing sampling and payer contracting and keep milking the base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong‑tenured PD brands with loyal users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong‑tenured PD brands show stable prescriber habits and consistent outcomes that protect a book delivering steady cash: Supernus reported roughly $1.2B in 2024 product sales, with limited volume growth but solid gross profit per script supporting margins near mid‑30s percent. Focus is on access maintenance rather than heavy expansion, and incremental efficiencies flow directly to cash flow, boosting free cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. specialty distribution channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eU.S. specialty distribution channels\u003c\/h3\u003e Supernus' well‑oiled distribution minimizes leakage and returns, sustaining fill rates above 95% and return rates below 3% in 2024. The network is built and amortized, making incremental units high margin and funding 2024 R\u0026amp;D and BD investments. Tight SLAs and lean inventory improved working capital, freeing cash to back higher‑risk pipeline bets.\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore payer contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCore payer contracts are locked into formulary positions that reduce churn and rebate volatility; with top PBMs managing approximately 75% of US prescriptions, 2024 renegotiations prioritized stability over splash. Small contractual tweaks—duration, price protection, specialty carve-outs—yield outsized cash uplift and steadier free cash flow. Protect these cash cows with targeted account management and monthly performance analytics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eLocked‑in formulary = lower churn\u003c\/li\u003e\n\u003cli\u003eTop PBMs ≈75% market reach\u003c\/li\u003e\n\u003cli\u003eMinor term changes → outsized cash impact\u003c\/li\u003e\n\u003cli\u003eProtect via targeted account management\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle‑managed SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLifecycle‑managed SKUs rely on packaging, dosing tweaks and minor enhancements to sustain demand with low incremental spend; they do not drive growth but generate steady cash flow. Supply reliability is the primary value lever, so keep COGS low and quality controls stringent to protect margins and uptime.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRole: cash generators\u003c\/li\u003e\n\u003cli\u003eDriver: supply reliability\u003c\/li\u003e\n\u003cli\u003eFocus: COGS down, quality up\u003c\/li\u003e\n\u003cli\u003eInvestment: minor, high ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e\u0026gt;1M\u003c\/strong\u003e scripts, \u003cstrong\u003e~40%\u003c\/strong\u003e margin, PBM reach \u003cstrong\u003e~75%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEpilepsy XR \u0026gt;1.0M scripts in 2024 with gross margin ~40%, low promo spend and predictable refills sustaining cash flow. PD brands contributed to ~ $1.2B product sales in 2024 with mid‑30s% margins, focusing on access retention. Distribution fill rates \u0026gt;95% and returns \u0026lt;3% cut leakage; top PBMs cover ~75% of US scripts, protecting steady free cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy XR scripts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReturn rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM reach\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Supernus Pharmaceuticals BCG Matrix you'll receive after purchase—no watermarks, no demo pages. It's fully formatted, market-informed, and ready to drop into your strategy decks. Buy once, download immediately, edit, print, or present—no surprises, just a clean, professional report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder, low‑velocity epilepsy SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder, low-velocity epilepsy SKUs for Supernus show low share (under 5%) in a flat-to-declining segment, tying up inventory and commercial attention with minimal return; industry epilepsy Rx volumes have been roughly flat to down low-single-digits in recent years. Turnarounds demand costly relaunches or marketing spends and rarely sustain share gains. Consider pruning slow SKUs or bundling them into payoff-driven combos to free cash and sales capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy PD add‑ons facing generic pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy PD add‑ons show minimal differentiation and face steep generic erosion; generic entry typically cuts branded volume by over 80% and prices by 60–90% within a year (IQVIA\/industry benchmarks). Tough reimbursement and prescriber fatigue mean share drips away despite marketing; cash contribution is marginal relative to total portfolio. Sunset plans now outweigh heroic reinvestment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall legacy ADHD formulations in stimulant‑heavy niches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSmall legacy ADHD formulations operate in a crowded stimulant-dominated market where generics account for over 80% of US ADHD prescriptions as of 2024. Entrenched competitors and rapid copycat launches limit pricing power; promotional spend yields minimal market-share gains. After gross-to-net impacts and PBM rebates these SKUs reach break-even at best. Recommend exit or sharply narrow focus to niche formulary pockets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche hospital‑only presentations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDogs: Niche hospital‑only presentations show tiny volumes, complex logistics and high service costs, yielding limited strategic value outside a few centers; they divert field and distribution resources better allocated to higher‑margin, broader market products, so divest or de‑prioritize.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow volume\u003c\/li\u003e\n\u003cli\u003eHigh logistics cost\u003c\/li\u003e\n\u003cli\u003eLimited strategic reach\u003c\/li\u003e\n\u003cli\u003eRecommendation: divest\/de‑prioritize\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑core international micro‑licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core international micro-licenses show fragmented demand and regulatory drag, delivering single-digit royalty economics (commonly 5–12% in comparable specialty pharma deals) and thin margins that often fail to cover fixed SG\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eManagement overhead and compliance costs frequently exceed payoff; without local commercial partners scaling is impractical and time-to-revenue extends beyond typical value-horizon for Supernus.\u003c\/p\u003e\n\u003cp\u003eRationalize the portfolio by exiting subscale territories and concentrating resources on high-opportunity regions and partnered deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003efragmented demand\u003c\/li\u003e\n\u003cli\u003eregulatory drag\u003c\/li\u003e\n\u003cli\u003ethin margins (≈5–12% royalties)\u003c\/li\u003e\n\u003cli\u003emanagement overhead \u0026gt; payoff\u003c\/li\u003e\n\u003cli\u003ehard to scale without local muscle\u003c\/li\u003e\n\u003cli\u003erecommend: rationalize portfolio\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e\u0026lt;5%\u003c\/strong\u003e share, ≈0 to -5% volumes, \u0026gt; \u003cstrong\u003e80%\u003c\/strong\u003e generics — divest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Dogs (older epilepsy SKUs, legacy PD add‑ons, small ADHD presentations, niche hospital forms, micro-licenses) show \u0026lt;5% share, flat-to-down volumes (≈0 to -5% recent), \u0026gt;80% generics in ADHD (2024), and royalty economics of ~5–12%; high logistics and SG\u0026amp;A erode margins—recommend divest or de‑prioritize to free cash and commercial capacity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume trend\u003c\/td\u003e\n\u003ctd\u003e≈0 to -5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD generic share (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecommendation\u003c\/td\u003e\n\u003ctd\u003eDivest\/de‑prioritize\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext‑gen ADHD indications and age expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext‑gen ADHD and age‑expansion targets sit in a large market—U.S. childhood ADHD diagnosis ~9.8% (CDC) and global ADHD therapeutics expected mid‑single to high‑single digit CAGR into 2024—yet share is not guaranteed. Success hinges on meaningful trial wins and payer alignment; commercialization timelines mean high burn before material revenue. Invest aggressively if robust early efficacy\/safety and formulary support appear, otherwise cut fast. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew CNS pipeline assets (depression, anxiety, impulse‑control)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew CNS pipeline assets targeting depression, anxiety and impulse‑control face a large unmet need—WHO estimates over 300 million people live with depression—yet the space is crowded with mixed clinical outcomes. Differentiation must be crystal‑clear to break through formulary and prescriber barriers. Clinical and access risks are real; fund winners, partner or shelve the rest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital adherence and real‑world data programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital adherence and real‑world data programs can lift persistency—WHO reports average adherence to long‑term therapies around 50%—and provide payer evidence of value. Adoption is uneven and early monetization is difficult, with digital interventions showing median adherence gains near 10 percentage points in meta‑analyses. If linked to improved outcomes, RWD can tip access decisions; pilot, measure, and scale only interventions that move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx‑US market entries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEx‑US market entries present clear growth runway—global pharma sales reached about $1.6 trillion in 2024—yet market access and local regulatory requirements are heavy lifts and vary by country.\u003c\/p\u003e\n\u003cp\u003eUpfront costs (registrations, local trials, launches) typically outpace early revenue; selective launches can limit spend while proof points are gathered.\u003c\/p\u003e\n\u003cp\u003eThe right local partner can accelerate reimbursements and bend the profitability curve; pilot launches in 2–3 markets before broader expansion are recommended.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth tag: global pharma ~ $1.6T (2024)\u003c\/li\u003e\n\u003cli\u003eRisk tag: high regulatory \u0026amp; access friction\u003c\/li\u003e\n\u003cli\u003eCost tag: upfront launch investments \u0026gt; early revenue\u003c\/li\u003e\n\u003cli\u003eStrategy tag: partner-led pilots in 2–3 markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew formulations and combo approaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNew formulations and combos could address ~50% chronic‑med adherence gaps and US nonadherence costs \u0026gt;$290B\/year (2024), improving tolerability and market penetration; however technical\/CMC risks often cause 6–18 month timeline slips. If clinical PK\/PD shows clear benefits the asset can convert to a Star; stage‑gate tightly and terminate quickly if signals fade.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdherence upside: ~50%\u003c\/li\u003e\n\u003cli\u003eCost context: \u0026gt;$290B (US, 2024)\u003c\/li\u003e\n\u003cli\u003eCMC risk: 6–18m delay\u003c\/li\u003e\n\u003cli\u003eAction: tight stage‑gate, kill fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. ADHD \u003cstrong\u003e9.8%\u003c\/strong\u003e, global pharma \u003cstrong\u003e$1.6T\u003c\/strong\u003e: clinical wins, payer access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge addressable markets (U.S. childhood ADHD 9.8% CDC; global pharma $1.6T 2024) but execution risk high; success needs clear clinical wins, payer access and durable differentiation. High upfront launch\/CMC costs (\u0026gt; $290B US nonadherence cost context) and 6–18m timeline risk. Prioritize assets with strong early signals; partner and pilot ex‑US launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003eU.S. ADHD 9.8%; global pharma $1.6T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk\u003c\/td\u003e\n\u003ctd\u003eHigh regulatory\/access; CMC 6–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\u003c\/td\u003e\n\u003ctd\u003eContext: US nonadherence \u0026gt;$290B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eStage‑gate, partner pilots 2–3 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098545164636,"sku":"supernus-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/supernus-bcg-matrix.png?v=1781806880","url":"https:\/\/pestel-analysis.com\/products\/supernus-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}